Patency, perfusion, performance--the desirable triplets of combination thrombolytic therapy.
Wilcox
R
R
D001241:Aspirin / Q000627:therapeutic use; D003326:Coronary Circulation / Q000502:physiology; D004359:Drug Therapy, Combination; D000077542:Eptifibatide; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D010455:Peptides / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D013300:Streptokinase / Q000627:therapeutic use; D015912:Thrombolytic Therapy; D014654:Vascular Patency / Q000187:drug effects
D005343:Fibrinolytic Agents; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D013300:Streptokinase; D000077542:Eptifibatide; D001241:Aspirin